These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 6790606

  • 1. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
    Jennings HJ, Lugowski C.
    J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606
    [Abstract] [Full Text] [Related]

  • 2. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
    Jennings HJ, Roy R, Gamian A.
    J Immunol; 1986 Sep 01; 137(5):1708-13. PubMed ID: 3091688
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein.
    Beuvery EC, Roy R, Kanhai V, Jennings HJ.
    Dev Biol Stand; 1986 Sep 01; 65():197-204. PubMed ID: 3104115
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
    Gudlavalleti SK, Lee CH, Norris SE, Paul-Satyaseela M, Vann WF, Frasch CE.
    Vaccine; 2007 Nov 14; 25(46):7972-80. PubMed ID: 17936445
    [Abstract] [Full Text] [Related]

  • 5. Analytical, toxicological and immunological consequences of the use of N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human use.
    Beuvery EC, Speijers GJ, Lutz BI, Freudenthal D, Kanhai V, Haagmans B, Derks HJ.
    Dev Biol Stand; 1986 Nov 14; 63():117-28. PubMed ID: 3091432
    [Abstract] [Full Text] [Related]

  • 6. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M, Cabrera O, Martinez I, Del Campo JM, Camaraza MA, Sotolongo F, Pérez O, Sierra G.
    Vaccine; 2007 Feb 26; 25(10):1798-805. PubMed ID: 17240485
    [Abstract] [Full Text] [Related]

  • 7. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.
    Peeters CC, Tenbergen-Meekes AM, Evenberg DE, Poolman JT, Zegers BJ, Rijkers GT.
    J Immunol; 1991 Jun 15; 146(12):4308-14. PubMed ID: 2040803
    [Abstract] [Full Text] [Related]

  • 8. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.
    Beuvery EC, Miedema F, van Delft R, Haverkamp J.
    Infect Immun; 1983 Apr 15; 40(1):39-45. PubMed ID: 6187693
    [Abstract] [Full Text] [Related]

  • 9. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1.
    Jennings HJ, Gamian A, Michon F, Ashton FE.
    J Immunol; 1989 May 15; 142(10):3585-91. PubMed ID: 2469720
    [Abstract] [Full Text] [Related]

  • 10. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid.
    Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe GR.
    J Immunol; 1998 May 15; 160(10):5028-36. PubMed ID: 9590252
    [Abstract] [Full Text] [Related]

  • 11. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N, Balmer P, Morris R, Kroll JS, Miller E.
    Clin Diagn Lab Immunol; 2004 Nov 15; 11(6):1100-4. PubMed ID: 15539513
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ.
    J Clin Invest; 1990 Nov 15; 86(5):1428-33. PubMed ID: 2243123
    [Abstract] [Full Text] [Related]

  • 13. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice.
    Beuvery EC, van Delft RW, Miedema F, Kanhai V, Nagel J.
    Infect Immun; 1983 Aug 15; 41(2):609-17. PubMed ID: 6409811
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
    Bartoloni A, Norelli F, Ceccarini C, Rappuoli R, Costantino P.
    Vaccine; 1995 Apr 15; 13(5):463-70. PubMed ID: 7543714
    [Abstract] [Full Text] [Related]

  • 15. Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.
    Coquillat D, Bruge J, Danve B, Latour M, Hurpin C, Schulz D, Durbec P, Rougon G.
    Infect Immun; 2001 Nov 15; 69(11):7130-9. PubMed ID: 11598089
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que JU, Hasler T, Cryz SJ.
    Southeast Asian J Trop Med Public Health; 1997 Mar 15; 28(1):91-8. PubMed ID: 9322290
    [Abstract] [Full Text] [Related]

  • 17. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods.
    Beuvery EC, vd Kaaden A, Kanhai V, Leussink AB.
    Vaccine; 1983 Dec 15; 1(1):31-6. PubMed ID: 6442499
    [Abstract] [Full Text] [Related]

  • 18. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
    Paoletti LC, Kasper DL, Michon F, DiFabio J, Jennings HJ, Tosteson TD, Wessels MR.
    J Clin Invest; 1992 Jan 15; 89(1):203-9. PubMed ID: 1729272
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR, Granoff DM, Barenkamp SJ, Powers DC, Kennedy D, Irby-Moore S, Homan SM, Mink CM.
    J Am Geriatr Soc; 2004 Nov 15; 52(11):1883-7. PubMed ID: 15507066
    [Abstract] [Full Text] [Related]

  • 20. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis.
    Jennings HJ, Lugowski C, Ashton FE.
    Infect Immun; 1984 Jan 15; 43(1):407-12. PubMed ID: 6418661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.